Skip to content

Transcranial Magnetic Treatment (TMS) in Unipolar Depression

Repetitive Transcranial Magnetic Stimulation (rTMS) in Unipolar Depression

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00186784
Enrollment
21
Registered
2005-09-16
Start date
2000-12-31
Completion date
2011-07-31
Last updated
2011-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unipolar Depression

Keywords

Repetitive Transcranial Magnetic Stimulation, TMS

Brief summary

Repetitive Transcranial Magnetic Stimulation (rTMS) can improve mood and decrease sadness in patients with depression. In this study, the investigators seek to increase their understanding about how rTMS improves depression, and to determine which form of rTMS is most effective for depression, when used in combination with antidepressant medication.

Detailed description

Patients will be assigned for 4 treatment arms, receiving either left high frequency plus right low frequency, or left high frequency plus right sham, or left sham, plus right low frequency, or left sham plus right sham treatment. All subjects will receive treatments for 10 days and will be followed for another 4 weeks.

Interventions

PROCEDURETranscranial Magnetic Stimulation (TMS)

treatment for 10 days

Sponsors

Queen's University, Kingston, Ontario
CollaboratorOTHER
St. Joseph's Healthcare Hamilton
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Major Depression * No physical health problems

Exclusion criteria

* History of Epilepsy * Metal in the head/neck or skull * Pacemaker * Pregnancy

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Rating ScalePre TMS and post TMS
Beck Depression Rating Scalepre TMS and post TMS

Secondary

MeasureTime frame
Quantitive Electroencephalographic(QEEG)activity and measures of regional cerebral blood flowpre TMS and post TMS as well as post phase II, second set of TMS

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026